Pegasys and Raynaud's phenomenon aggravated - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon aggravated is reported as a side effect among people who take Pegasys (peginterferon alfa 2a), especially for people who are female, 40-49 old, have been taking the drug for 1 - 2 years also take Copegus, and have Insomnia.

The phase IV clinical study analyzes which people have Raynaud's phenomenon aggravated when taking Pegasys. It is created by eHealthMe based on reports of 57,338 people who have side effects when taking Pegasys from the FDA, and is updated regularly.

What is Pegasys?

Pegasys has active ingredients of peginterferon alfa 2a. It is often used in hepatitis c. eHealthMe is studying from 57,446 Pegasys users. Check the latest studies of Pegasys.

What is Raynaud's phenomenon aggravated?

Raynaud's phenomenon aggravated (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 674 drugs and 348 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon aggravated.

On Jul, 11, 2026

57,338 people reported to have side effects when taking Pegasys.
Among them, 24 people (0.04%) have Raynaud's phenomenon aggravated.

Could Pegasys cause Raynaud's phenomenon aggravated?

Among these 24 people:

How long have people been on Pegasys when they have Raynaud's phenomenon aggravated? *

What is the gender of people who have Raynaud's phenomenon aggravated when taking Pegasys? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Raynaud's phenomenon aggravated when taking Pegasys? *

What are other drugs people take besides Pegasys? *

What are other side effects people have besides Raynaud's phenomenon aggravated? *

Anaemia (lack of blood): 6 people, 25.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 6 people, 25.00%
Fatigue (feeling of tiredness): 6 people, 25.00%
Leukopenia (less number of white blood cells in blood): 5 people, 20.83%
Extremity Necrosis (death of body tissue of arms and legs): 5 people, 20.83%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 16.67%
Dyspnea (difficult or laboured breathing): 4 people, 16.67%
White Blood Cell Count Decreased: 3 people, 12.50%
Fever: 3 people, 12.50%
Headache (pain in head): 3 people, 12.50%

What are the existing conditions these people have? *

Insomnia (sleeplessness): 5 people, 20.83%
Depression: 2 people, 8.33%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 1 person, 4.17%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Pegasys and have Raynaud's phenomenon aggravated?

- Check whether Raynaud's phenomenon aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pegasys:

Pegasys (57,446 reports)

Browse all side effects of Pegasys:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Raynaud's phenomenon aggravated:

Raynaud's phenomenon aggravated (674 drugs)

Browse all the conditions that are associated with Raynaud's phenomenon aggravated:

Raynaud's phenomenon aggravated (348 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on peginterferon alfa 2a (the active ingredients of Pegasys) and Pegasys (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.